Asset Details
Do you wish to reserve the book?
A Cluster-Randomized Effectiveness Trial of Vi Typhoid Vaccine in India
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
A Cluster-Randomized Effectiveness Trial of Vi Typhoid Vaccine in India
Do you wish to request the book?
A Cluster-Randomized Effectiveness Trial of Vi Typhoid Vaccine in India
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
A Cluster-Randomized Effectiveness Trial of Vi Typhoid Vaccine in India
2009
Overview
Typhoid remains an important cause of illness and death in the developing world. In this phase 4 trial in Kolkata, India, 37,673 subjects were vaccinated with either Vi typhoid vaccine or hepatitis A vaccine. The Vi vaccine was approximately 61% effective in preventing typhoid infection in vaccine recipients and was 44% effective in unvaccinated members of the same clusters as the Vi-vaccine recipients, suggesting that Vi vaccination has indirect benefits for those in close contact with vaccine recipients.
The Vi vaccine was approximately 61% effective in preventing typhoid infection in vaccine recipients and was 44% effective in unvaccinated members of the same clusters. Vi vaccination has indirect benefits for those in close contact with vaccine recipients.
Typhoid fever, caused by
Salmonella enterica
serotype Typhi (
S.
Typhi), results in an estimated 216,000 to 600,000 deaths annually, almost all in developing countries.
1
,
2
Among licensed, newer-generation typhoid vaccines, the injectable Vi polysaccharide vaccine has several characteristics that make it attractive for use in developing countries. Given in a single dose, the Vi vaccine is sold at prices as low as 50 cents per dose. Moreover, the Vi vaccine is produced by two international manufacturers and several manufacturers in developing countries, which have licensed it for persons 2 years of age or older.
3
–
5
Despite a World . . .
Publisher
Massachusetts Medical Society
Subject
/ Adult
/ Antibodies, Bacterial - blood
/ Bacterial diseases of the digestive system and abdomen
/ Biological and medical sciences
/ Child
/ Hepatitis A Vaccines - adverse effects
/ Humans
/ India
/ Paratyphoid Fever - epidemiology
/ Polysaccharides, Bacterial - adverse effects
/ Polysaccharides, Bacterial - immunology
/ Salmonella typhi - immunology
/ Typhoid
/ Typhoid Fever - epidemiology
/ Typhoid Fever - prevention & control
/ Typhoid-Paratyphoid Vaccines - adverse effects
/ Typhoid-Paratyphoid Vaccines - immunology
/ Vaccines
